Roche signs up Dicerna in a $200M-plus cash alliance to help develop a hep B cocktail, capping the biotech's big year
Over the past year we’ve seen a string of collaborations between Big Pharma players and some up-and-coming biotechs over next-gen approaches to hepatitis B. Now …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
